On October 17, 2025 EORTC reported strong presence at this year’s ESMO (Free ESMO Whitepaper) Congress, running from 17 to 21 October in Berlin. We will be presenting ten abstracts, two of which are mini oral presentations, alongside six poster displays and two e-posters. Additionally, we will participate in three sessions: a special session highlighting patient-reported outcomes, an educational session showcasing perspectives on treatment optimisation and a patient advocacy session discussing diversity and inclusion in clinical trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Further details can be found in the table below.
EORTC ABSTRACTS
DEVELOPMENT OF A PATIENT INVOLVEMENT FRAMEWORK FOR THE EORTC: INSIGHTS FROM A SURVEY WITH PATIENT PARTNERS AND ONCOLOGY PROFESSIONALS.
Iryna Shakhnenko, Belgium Sunday, 19 October 15:50 – 15:55
Type: Mini Oral session
Room: Bochum Auditorium – Hall 6.1
Abstract number: 2287MO
DISCONTINUATION AND ATTRITION RATES IN PHASE II OR PHASE III FIRST-LINE RANDOMIZED CLINICAL TRIALS (RCTS) OF SOLID TUMORS
Eva Blondeaux, Italy Monday, 20 October 10:45 – 10:50
Type: Mini Oral session
Room: Bochum Auditorium – Hall 6.1
Abstract number: 2279MO
EORTC GUCG 2238 DE-ESCALATE: A PRAGMATIC TRIAL TO REVISIT INTERMITTENT ANDROGEN-DEPRIVATION THERAPY IN METASTATIC HORMONE-NAÏVE PROSTATE CANCER IN THE ERA OF NEW AR PATHWAY INHIBITORS.
Guillaume Grisay, Belgium Saturday, 18 October 12:00-12:45
Type: Poster session
Abstract number: 2519TiP
EFFICACY OF [177LU]LU-PSMA-617 IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA: A MULTICENTRE SINGLE-ARM PHASE II TRIAL (RENALUT)
Emmanuel Seront, Belgium Saturday, 18 October 12:00-12:45
Type: Poster session
Abstract number: 2625P
DEVELOPMENT OF A PATIENT-REPORTED OUTCOME MEASURE FOR INDIVIDUALS AT RISK FOR HEREDITARY CANCER – PHASE 1-3A OF THE EORTC QLQ-HCR30
Veronika Engele & Anne Oberguggenberger, Austria Sunday, 19 October 2025 12:00-12:45
Type: Poster session
Abstract number: 2579P
OUTCOMES OF FIRST-LINE CHEMOTHERAPY IN ADVANCED/METASTATIC ADULT FIBROSARCOMA: POOLED ANALYSIS OF CLINICAL TRIALS FROM THE EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER SOFT TISSUE AND BONE SARCOMA GROUP
Fernando Campos, Brazil Monday, 20 October 12:00-12:45
Type: Poster session
Abstract number: 2739P
EORTC 2014-HNCG PROLONG: PEMBROLIZUMAB AND RADIOTHERAPY FOR OLIGOMETASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, RANDOMIZED PHASE III TRIAL
Irene Braña, Spain Monday, 20 October 12:00-12:45
Type: Poster session
Abstract number: 1443TiP
MOLECULAR LANDSCAPE OF TUMORS FROM LONG-TERM SURVIVORS WITH GLIOBLASTOMA: LESSONS FROM ETERNITY (EORTC 1419)
Michael Weller, Switzerland Monday, 20 October 12:00-12:45
Type: Poster session
Abstract number: 667P
DEVELOPMENT OF AN EORTC STRATEGY TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN CANCER PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS: PHASE 1 AND 2
Louis Fox, United Kingdom Type: E-Poster
Abstract number: 3191eP
EORTC GUCG 2418 STARBUST: "STRATEGIES FOR TREATMENT ADAPTATION FOLLOWING RE-EVALUATION OF THE BLADDER AFTER USING PRIMARY NEOADJUVANT SYSTEMIC THERAPIES": AN EORTC PLATFORM TRIAL
Guillaume Grisay, Belgium Type: E-Poster
Abstract number: 3134eTiP
SESSIONS
SETTING INTERNATIONAL STANDARDS IN ANALYSING PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE ENDPOINTS (SISAQOL-IMI): 4-YEAR OUTCOME
Madeline Pe, Belgium SPECIAL SESSION
Friday, 17 October 14:35 – 14:50
Flensburg Auditorium – Hall 23
PERSPECTIVES FOR TREATMENT OPTIMISATION: CONSIDERATIONS FROM A HCP AND TRIALIST
Denis Lacombe, Belgium EDUCATIONAL SESSION
Sunday, 19 October 09:00 – 09:15
Bochum Auditorium – Hall 6.1
DIVERSITY, EQUITY AND INCLUSION IN CLINICAL TRIALS
Denis Lacombe, Belgium PATIENT ADVOCACY SESSION
Sunday, 19 October 17:15-17:30
Bochum Auditorium – Hall 6.1
(Press release, EORTC, OCT 17, 2025, View Source [SID1234656732])